Lai, C.-H.; Shi, H.-Y.; Tsai, C.-E.; Yang, Y.-C.; Chiu, S.-U.F.
Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model. Cancers 2024, 16, 813.
https://doi.org/10.3390/cancers16040813
AMA Style
Lai C-H, Shi H-Y, Tsai C-E, Yang Y-C, Chiu S-UF.
Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model. Cancers. 2024; 16(4):813.
https://doi.org/10.3390/cancers16040813
Chicago/Turabian Style
Lai, Chun-Huang, Hon-Yi Shi, Cheng-En Tsai, Yuan-Chieh Yang, and Si-Un Frank Chiu.
2024. "Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model" Cancers 16, no. 4: 813.
https://doi.org/10.3390/cancers16040813
APA Style
Lai, C.-H., Shi, H.-Y., Tsai, C.-E., Yang, Y.-C., & Chiu, S.-U. F.
(2024). Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model. Cancers, 16(4), 813.
https://doi.org/10.3390/cancers16040813